Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
06 Nov 2024: MacroGenics pauses work on vobra duo ADC pending mature survival data
- MacroGenics has paused investment in vobra duo and related studies pending updated data from the Phase 2 TAMARACK trial for metastatic castration-resistant prostate cancer, with PFS data expected by early 2025
- The company will assess final PFS results, safety, and the competitive landscape before deciding on the next steps, including potential additional studies
- Safety concerns, including five patient deaths in the TAMARACK trial, have impacted stock performance and led to a more cautious approach
- MacroGenics continues to focus on the B7-H3 target for ADCs, with plans to advance other candidates like MGC026, which uses a topoisomerase I inhibitor payload developed by Synaffix
